218 related articles for article (PubMed ID: 34496019)
1. A novel activating JAK1 mutation in chronic eosinophilic leukemia.
Shomali W; Damnernsawad A; Theparee T; Sampson D; Morrow Q; Yang F; Fernandez-Pol S; Press R; Zehnder J; Tyner JW; Gotlib J
Blood Adv; 2021 Sep; 5(18):3581-3586. PubMed ID: 34496019
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: A nationwide CEREO study.
Groh M; Fenwarth L; Labro M; Boudry A; Fournier E; Wemeau M; Marceau-Renaut A; Daltro de Oliveira R; Abraham J; Barry M; Blanche P; Bodard Q; Braun T; Chebrek S; Decamp M; Durel CA; Forcade E; Gerfaud-Valentin M; Golfier C; Gourguechon C; Grardel N; Kosmider O; Martis N; Melboucy Belkhir S; Merabet F; Michon A; Moreau S; Morice C; Néel A; Nicolini FE; Pascal L; Pasquier F; Pieragostini A; Roche-Lestienne C; Rousselot P; Terriou L; Thiebaut-Bertrand A; Viallard JF; Preudhomme C; Kahn JE; Lefevre G; Duployez N;
Am J Hematol; 2024 Jun; 99(6):1108-1118. PubMed ID: 38563187
[TBL] [Abstract][Full Text] [Related]
3. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
4. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.
Wang SA; Tam W; Tsai AG; Arber DA; Hasserjian RP; Geyer JT; George TI; Czuchlewski DR; Foucar K; Rogers HJ; Hsi ED; Bryan Rea B; Bagg A; Dal Cin P; Zhao C; Kelley TW; Verstovsek S; Bueso-Ramos C; Orazi A
Mod Pathol; 2016 Aug; 29(8):854-64. PubMed ID: 27174585
[TBL] [Abstract][Full Text] [Related]
6. Chronic Eosinophilic Leukaemia Associated with JAK2 Exon 13 Insertion/Deletion Mutations.
Lafferty N; Salmon M; Cross NCP; Singer I; Cooney A; Jayaprakash R
Acta Haematol; 2022; 145(2):201-206. PubMed ID: 34515041
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
[TBL] [Abstract][Full Text] [Related]
8. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic Work-Up of Hypereosinophilia.
Wang SA
Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056
[TBL] [Abstract][Full Text] [Related]
10. [Chronic neutrophilic leukemia/chronic eosinophilic leukemia].
Kawashima I; Kirito K
Rinsho Ketsueki; 2023; 64(10):1326-1334. PubMed ID: 37914248
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
Odinius TO; Buschhorn L; Wagner C; Hauch RT; Dill V; Dechant M; Buck MC; Shoumariyeh K; Moog P; Schwaab J; Reiter A; Brockow K; Götze K; Bassermann F; Höckendorf U; Branca C; Jost PJ; Jilg S
J Cancer Res Clin Oncol; 2022 Feb; 148(2):331-340. PubMed ID: 34654952
[TBL] [Abstract][Full Text] [Related]
12. Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia.
Mattis DM; Wang SA; Lu CM
Am J Clin Pathol; 2020 Aug; 154(3):305-318. PubMed ID: 32525541
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.
Wang SA; Hasserjian RP; Tam W; Tsai AG; Geyer JT; George TI; Foucar K; Rogers HJ; Hsi ED; Rea BA; Bagg A; Bueso-Ramos CE; Arber DA; Verstovsek S; Orazi A
Haematologica; 2017 Aug; 102(8):1352-1360. PubMed ID: 28495918
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
[TBL] [Abstract][Full Text] [Related]
15. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
16. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
17. Identification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CEL.
Li B; Zhang G; Li C; He D; Li X; Zhang C; Tang F; Deng X; Lu J; Tang Y; Li R; Chen Z; Duan C
PLoS One; 2012; 7(4):e34912. PubMed ID: 22523564
[TBL] [Abstract][Full Text] [Related]
18. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD
Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727
[TBL] [Abstract][Full Text] [Related]
19. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia.
Li Q; Li B; Hu L; Ning H; Jiang M; Wang D; Liu T; Zhang B; Chen H
Oncotarget; 2017 May; 8(21):34687-34697. PubMed ID: 28410228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
